Treatment of Transformed Follicular Lymphoma in Anthracycline-Naive Patients
Histological transformation of follicular lymphoma marks a critical change in disease biology requiring prompt frontline intervention. In patients with no prior anthracycline exposure, a specific evidence-based regimen is indicated as the standard approach.
Clinical Scenario
This protocol applies to patients with transformed follicular lymphoma who have had no prior anthracycline-based therapy. Anthracycline-naive status is the defining criterion — it preserves eligibility for full-intensity frontline immunochemotherapy that would otherwise be contraindicated or already exhausted.
Treatment Approach
Frontline management for anthracycline-naive transformed FL centres on an anthracycline-based immunochemotherapy combination. The complete regimen, dosing schedule, and clinical algorithm are detailed in the full protocol.
References
DOI: 10.3390/cancers18030395
R-CHOP is recommended for anthracycline-naïve tFL patients, largely based on extrapolation from de novo DLBCL data (1B).
View source ↗